profit from every $100 of sales.
$0$100
Regencell Bioscience Holdings
$4.94-3.61% today
-62.3% in 1 year
1-year low $4.781-year high $52.88
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Regencell Bioscience Holdings sold, what it kept, and what it did with the cash.
Sales went from $0 in 2021 to $0 in 2024, with -$4.30 million of profit last year.
SalesProfit
Regencell Bioscience Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Regencell Bioscience Holdings | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Regencell Bioscience Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -1 | -8 | -6 | -5 | |
| -1 | -7 | -6 | -4 | |
| -1 | -7 | -6 | -4 | |
| – | -0.02 | -0.01 | -0.01 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 0 | 18 | 13 | 8 |
| Cash | 0 | 6 | 2 | 3 |
| Total debt | 4 | 1 | 0 | 0 |
| Total liabilities | 4 | 1 | 1 | 0 |
| -4 | 17 | 12 | 8 | |
| – | 487 | 494 | 494 | |
| – | -33.7% | -39.7% | -45.1% | |
| 33.7% | -43.6% | -48.8% | -52.3% |
Cash flow
| In millions of USD | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| -1 | -5 | -5 | -4 | |
| – | 1 | 0 | 0 | |
| -1 | -6 | -5 | -4 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 3 | 1 | 0 |
Valuation
- –
- –
- –
- 194.3×
- –
- –
- –
- -0.3%
- -0.5%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -69.6%
- -47.8%
- -231.9%
- -233.9%
- -529.3%
- –
Growth
- –
- –
- +18.5%
- –
- +0.5%
Financial health
- -1.2×
- 0.02
- 12.8%
- –
- 10.77
- 1.42
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 952
Bottom 20%of 884
Bottom 37%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Nov 18, 2025 | -0.00 | – | – |
| Jun 26, 2025 | -0.14 | – | – |
| Jan 26, 2024 | 0.00 | – | – |
| Jan 30, 2023 | -0.01 | – | – |
| Dec 30, 2021 | -0.01 | – | – |
| Dec 30, 2020 | 0.00 | – | – |
| Jun 30, 2020 | 0.00 | – | – |
| Dec 30, 2019 | 0.00 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
25No pass
Benjamin Graham
60Pass
Philip Fisher
36No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
30No pass
Terry Smith
26No pass
Questions about Regencell Bioscience Holdings
Is Regencell Bioscience Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Regencell Bioscience Holdings AI analysis
What does Regencell Bioscience Holdings do?
Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It is in Drug Manufacturers - Specialty & Generic, based in Causeway Bay, Hong Kong, with 10 employees.
Does Regencell Bioscience Holdings pay a dividend?
No. Regencell Bioscience Holdings does not pay a dividend at the moment.
Is Regencell Bioscience Holdings stock halal?
Yes. Regencell Bioscience Holdings passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has Regencell Bioscience Holdings stock done over the past year?
Down 62.3% over the past twelve months, to $4.94. It traded between $4.78 and $52.88 and is 90.7% below its high.
Who are Regencell Bioscience Holdings's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Regencell Bioscience Holdings's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.